ReviewJournal of cardiovascular translational research2009
MicroRNAs challenge the status quo of therapeutic targeting.
Review in Journal of cardiovascular translational research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Plasma Circulating Extracellular RNAs in Left Ventricular Remodeling Post-Myocardial Infarction.EBioMedicine · 2018Trial
- Recent trends in miRNA therapeutics and the application of plant miRNA for prevention and treatment of human diseases.Future journal of pharmaceutical sciences · 2022Review
- miRNome in myocardial infarction: Future directions and perspective.World journal of cardiology · 2014Review
- Expression of microRNA-1, microRNA-133a and Hand2 protein in cultured embryonic rat cardiomyocytes.In vitro cellular & developmental biology. Animal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are recently discovered posttranscriptional regulators of gene expression that have become a cause célèbre. There are currently more than 600 miRNAs identified in humans that are estimated to regulate about one third of all messenger RNA (mRNA). Because miRNA levels were found widely deregulated in diseases, they have been implicated in the underlying pathogenesis. In addition, the changes in their expression patterns are proving to be reliable diagnostic and prognostic measures. But the specific mRNA targets and, hence, function of each miRNA is still work-in-progress. This information would be necessary before fully exploiting miRNA for therapeutic purposes. In this review we will discuss why miRNAs are considered major posttranscriptional regulators and how they impact gene expression and cell function during cardiac hypertrophy and failure. In addition, we will highlight their potential for therapeutic targeting.
Indexed as
Identifiers
20559973What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.